21例原发乳腺淋巴瘤临床分析并文献复习

目的:探讨原发乳腺淋巴瘤(primary breast lymphoma,PBL)的临床、病理特点、诊断、治疗方法及预后.方法:回顾性分析中山大学附属肿瘤医院1998年至2015年收治的21例PBL住院患者一般病例资料、分析其疾病特征、治疗及预后等情况.结果:21例中患者均为女性,年龄13~78岁,中位年龄41岁.ⅠE期12例、ⅡE期4例、ⅣE期5例,病理类型以弥漫大B细胞淋巴瘤为主(17/21例),治疗及预后:全组患者9例(42.9%)接受联合化放疗,11例(52.4%)单纯化疗,化疗方案以CHOP(7例)和RCHOP(11例)为主.中位随访42个月(3~126月),全组中位生存期56月,3年总生存率为84%,5年总生存率为78%.化疗联合靶向与单纯化疗相比、化疗联合放疗与单纯化疗相比,5年总生存率均无显著差异(88.2%和76.5%,P=0.77;84.3%和72.6%,P=0.38).结论:PBL接受以化疗为主的治疗,总体预后较好.

Primary breast lymphoma-A report of 21 cases with literature review

Objective:To investigate the clinical and pathological characteristics,diagnosis,treatment and prognosis of primary breast lymphoma(PBL).Methods:Clinical records of 21 PBL patients diagnosed between 1998 and 2015 in Sun-Yatsen university cancer center were retrospectively analyzed.Results:The patients were all female,aged between 13 to 78 years,with the median age of 41 years old.12 patients had ⅠE disease,4 patients had ⅡE disease and 5 had ⅣE disease.17/21 had diffuse large B cell lymphoma(DLBCL).Nine patients(42.9%) received chemotherapy and radiation,and 11(52.4%) received chemotherapy.Chemotherapy regimens mainly consisted of CHOP(n=7) and R-CHOP(n=11).Median follow-up duration was 42 months(ranged from 3 to 126 months).Median survival time was 56 months.The 3-year survival rate was 84% and the 5-year survival rate was 78%.Compared with chemotherapy,chemotherapy plus targeted therapy and chemotherapy plus radiation did not have statistical difference in 5-year survival rate(88.2% versus 76.5%,P=0.77 and 84.3% versus 72.6%,P=0.38,respectively).Conclusion:Patients with PBL had good response to chemotherapy,and the prognosis were generally optimal.